Cue Biopharma, Inc. Logo

Cue Biopharma, Inc.

Develops injectable biologics to selectively activate T cells for oncology & autoimmune disease.

CUE | US

Overview

Corporate Details

ISIN(s):
US22978P1066
LEI:
Country:
United States of America
Address:
40 GUEST STREET, 2135 BOSTON
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company that develops a novel class of injectable biologics to selectively engage and modulate disease-specific T cells. The company's proprietary Immuno-STAT™ (Selective Targeting and Alteration of T cells) platform engineers therapeutics designed to mimic natural immune signals. This approach aims to selectively expand and activate specific immune cells directly within the patient's body, mobilizing the immune system to treat serious diseases. Cue Biopharma's pipeline focuses on developing precision immunotherapies for oncology and autoimmune and inflammatory diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cue Biopharma, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cue Biopharma, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cue Biopharma, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

StemRIM Inc. Logo
Developing regenerative medicines that use the body's own stem cells to treat intractable diseases.
Japan
4599
STENOCARE A/S Logo
Develops and distributes prescription medical cannabis oils in Northern Europe and Australia.
Denmark
STENO
Stoke Therapeutics, Inc. Logo
Developing RNA-based medicines for genetic diseases by increasing protein from the healthy gene.
United States of America
STOK
ST PHARM CO., LTD. Logo
A global CDMO specializing in APIs and RNA therapeutics for the gene therapy market.
South Korea
237690
Structure Therapeutics Inc. Logo
Develops oral small molecule drugs for chronic conditions like metabolic diseases and obesity.
United States of America
GPCR
Sugentech, Inc. Logo
Develops advanced in-vitro diagnostic systems for hospitals, clinics, and at-home use.
South Korea
253840
SUHEUNG CO.,LTD. Logo
Global manufacturer of capsules and contract manufacturing for pharma/nutraceutical industries.
South Korea
008490
Sumitomo Pharma Co., Ltd. Logo
R&D pharma creating medicines for oncology, psychiatry & neurology, focusing on Japan & the US.
Japan
4506
Summit Therapeutics Inc. Logo
Advancing a Phase 3 bispecific antibody for lung cancer and other solid tumors.
United States of America
SMMT
SunBio, Inc. Logo
Develops biopharmaceuticals and devices like artificial blood using proprietary PEGylation technology.
South Korea
067370

Talk to a Data Expert

Have a question? We'll get back to you promptly.